Cancer News and Research

Latest Cancer News and Research

Watson Laboratories' ANDA for generic Toprol XL tablets receives FDA approval

Watson Pharmaceuticals, Inc., today announced that its subsidiary, Watson Laboratories, Inc. - Florida, has received approval from the United States Food and Drug Administration on its Abbreviated New Drug Application for metoprolol succinate extended-release tablets USP in the 100 and 200 mg strengths, the generic equivalent to AstraZeneca's Toprol XL® tablets.

16 Apr 2010

CycleBeads Conception Kit for women contemplating pregnancy

A scientifically-based tool developed by researchers from Georgetown University's Institute for Reproductive Health to help women prevent pregnancy naturally, is now being used by a growing number of women to help plan pregnancy.

16 Apr 2010

Stemgent, Pfizer announce collaboration and research licensing agreement

Stemgent, Inc. and Pfizer Inc. today announced a collaboration and research licensing agreement that will lead to certain research reagents developed or discovered by Pfizer being made available to the global research community through Stemgent. Stemgent provides research tools and services to institutions, companies and universities in advancing in vitro and in vivo non-human stem cell research.

16 Apr 2010

Regulus Therapeutics' metabolic disease program data presented at Diabetes Keystone Symposium

Regulus Therapeutics Inc. today announced that new data from its metabolic disease program were presented at the "Diabetes" Keystone Symposium held April 12-17 in Whistler, British Columbia. The new pre-clinical research findings showed that therapeutic oligonucleotides targeting microRNA are able to improve insulin resistance and normalize plasma glucose in mouse models of diabetes while having no significant effect on glucose or insulin levels in normal mice.

16 Apr 2010

Study on primary cilia formation may lead to new therapies for ciliopathies

A team of scientists at the University of California, San Diego School of Medicine have identified a network of genes that initiate and manage cilia formation. Although scientists have known about cilia for decades, only recently have they discovered their role in disease. This new discovery, which may lead to new therapies for ciliopathies, will appear in the April 15 edition of Nature.

16 Apr 2010

CINJ celebrates National Library Week

The Cancer Institute of New Jersey (CINJ) joins communities, schools and other institutions across the nation in celebrating the contributions of their libraries and librarians during this year's National Library Week (April 11 - 17).

16 Apr 2010

Current screening methods for FOBT are often not appropriate

More than 75 percent of primary care physicians in the United States who order or perform the fecal occult blood test as a screening option for colorectal cancer perform an in-office test rather than relying on the home-based test, even though the home-based test is more accurate, a study by the Centers for Disease Control and Prevention has found.

16 Apr 2010

Research may help develop simplified test for early detection of breast cancer

Researchers at the University of Arkansas are building a library of synthetically produced antibodies that can detect and rapidly validate proteins secreted by breast cancer cells. Their work will accelerate the process of developing a simple blood test for early detection of breast cancer.

16 Apr 2010

Vertex Pharmaceuticals announces results from Phase 1b clinical trial of VX-222

In conjunction with an oral presentation at the 45th Annual Meeting of the European Association for the Study of the Liver in Vienna, Vertex Pharmaceuticals Incorporated today announced results from a Phase 1b clinical trial of the investigational oral hepatitis C virus polymerase inhibitor, VX-222. In the trial, treatment with VX-222 for three days was well-tolerated, with all adverse events being mild to moderate in severity.

16 Apr 2010

Albert Einstein College of Medicine of Yeshiva University receives funds to expand stem cell research capabilities

Albert Einstein College of Medicine of Yeshiva University has been awarded $10 million from the National Institutes of Health to expand its stem cell research capabilities. The funds will be used to create new laboratories in order to increase its already substantial base of stem cell investigators.

16 Apr 2010

Kidney expert receives international award

Professor Jonathan Craig from the School of Public Health has been honoured for his contribution to the study of kidney disease. The US-based National Kidney Foundation awarded Professor Craig with its 2010 International Distinguished Medal, recognising outstanding accomplishments in the field of nephrology.

16 Apr 2010

Research may provide better clinical outcomes for patients with aggressive type of brain cancer

A study conducted by a collaborative team led by researchers from the University of Southern California (USC) may lead to better insight into the clinical outcome for some patients with a particularly aggressive type of brain cancer. The research may also provide a framework for development of targeted drug treatments.

16 Apr 2010

Advaxis initiates Phase 2 clinical trial of ADXS11-001 for treatment of CIN

Advaxis, Inc., the live, attenuated Listeria monocytogenes (Listeria) immunotherapy company, initiated the Company's first clinical trial site in its randomized, single blind, placebo-controlled, Phase 2 clinical trial of ADXS11-001 for the treatment of cervical intraepithelial neoplasia.

16 Apr 2010

Study links cancer growth to sugar-based modification found naturally in the body

Researchers at Drexel University College of Medicine have discovered that a certain type of sugar found naturally in the body is elevated in breast cancer cells and is critical for cancer growth and movement. When researchers reduced and normalized the levels of this sugar, they were able to slow the growth of the cancer cells and block invasion. The findings, published in the March 1 issue of Oncogene, represent a potential new therapeutic target for treating aggressive forms of breast cancer.

15 Apr 2010

Sorrento Therapeutics completes construction of fully human mAbs library

Sorrento Therapeutics, Inc. today announced that it has completed the construction of an extensive library of full-length, fully human monoclonal antibodies (mAbs). Initial analysis indicates a potential diversity of more than one trillion unique mAbs. The company believes this makes its library the largest full-length, fully human antibody library available for drug discovery and development partnerships.

15 Apr 2010

Celgene, Agios Pharmaceuticals form global strategic collaboration on targeting cancer metabolism

Celgene Corporation and Agios Pharmaceuticals Inc., a privately-held biotechnology company, today announced the formation of a global strategic collaboration focused on targeting cancer metabolism. The goal of the collaboration is to discover, develop, and deliver novel disease-altering therapies in oncology based on the transformational science of Agios' innovative cancer metabolism research platform. This platform is based on the concept that targeting key metabolic enzymes unique to rapidly proliferating cancer cells can "starve" the cancer.

15 Apr 2010

Exclusive licensing practices slows innovation in gene testing market

Exclusive licenses to gene patents, most of which are held by academic institutions and based on taxpayer-funded research, do more to block competition in the gene testing market than to spur the development of new technologies for gauging disease risk, say researchers at the Duke Institute for Genome Sciences & Policy (IGSP).

15 Apr 2010

Momenta Pharmaceuticals to present data on M402 drug candidate at 101st AACR meeting

Momenta Pharmaceuticals, Inc., a biotechnology company specializing in the characterization and engineering of complex mixture drugs, today announced that preclinical data for its novel drug candidate, M402, will be presented at the 101st Annual Meeting of the American Association for Cancer Research (AACR). The meeting will be held April 17-21, 2010 in Washington, DC.

15 Apr 2010

Complete Women's Imaging selects Merge Healthcare as IT partner

Merge Healthcare today announced that it was selected by Complete Women's Imaging, P.C., a designated Breast Imaging Center of Excellence by the American College of Radiology (ACR) and the Commission on Breast Imaging, to provide a complete diagnostic imaging workflow and physician reporting solution to the Atlantic Coastal Plain region of New York.

15 Apr 2010

Early, accurate detection of superficial bladder cancer with Olympus PDD

With Olympus photodynamic diagnosis (PDD), superficial bladder cancer can be detected earlier, easier and more accurately. Bladder cancer is diagnosed by cystoscopy, the endoscopic introduction of a light source through the urethra (transurethral) into the bladder. The imaging technology PDD uses blue light to increase the contrast between tumour tissue (red) and healthy tissue (blue).

From Evident Corporation - Life Sciences 15 Apr 2010